Activin A/ACVR2A axis inhibits epithelial-to-mesenchymal transition in colon cancer by activating SMAD2

Colorectal Cancer is one of the most common malignancies worldwide. Liver metastasis is the major direct cause of colorectal cancer-related deaths. Although radical resection is the most effective treatment for colorectal Cancer liver metastasis, several patients are not eligible for surgery. Therefore, there is a need to develop novel treatments based on the understanding of the biological mechanisms underlying liver metastasis in colorectal Cancer. This study demonstrated that Activin A/ACVR2A inhibits colon Cancer cell migration and invasion, as well as suppresses the epithelial-to-mesenchymal transition of mouse colon Cancer cells. This finding has been further validated in animal experiments. Mechanistic studies revealed that Activin A binds to SMAD2 (instead of SMAD3) and activates its transcription. Analysis of the paired clinical samples further confirmed that the expression levels of ACVR2A and SMAD2 were the highest in adjacent healthy tissues, followed by primary colon Cancer tissues and liver metastasis tissues, suggesting that ACVR2A downregulation may promote colon Cancer metastasis. Bioinformatics analysis and clinical studies demonstrated that ACVR2A downregulation was significantly associated with liver metastasis and poor disease-free and progression-free survival of patients with colon Cancer. These results suggest that the Activin A/ACVR2A axis promotes colon Cancer metastasis by selectively activating SMAD2. Thus, targeting ACVR2A is a potential novel therapeutic strategy to prevent colon Cancer metastasis.

ACVR2A; SMAD2; activin A; colon cancer; epithelial-to-mesenchymal transition; liver metastasis.